Phaseline

Targets › NCAM1

NCAM1 (Neural cell adhesion molecule 1): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Neurology, Oncology; next expected readout Oct 2028.

This protein is a cell adhesion molecule involved in neuron-neuron adhesion, neurite fasciculation, outgrowth of neurites, etc.; FUNCTION: (Microbial infection) Acts as a receptor for rabies virus..; FUNCTION: (Microbial infection) Acts as a receptor for Zika virus. (UniProt, P13591)

Open in Phaseline: the race on NCAM1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
S.BiomedicsPSA-NCAM(+) NPC (neural precursor cells derived from human embryonic stem cell l
Neural precursor cell transplantation therapy
NCAM1Phase 1Spinal Cord Injury, AcuteOct 2028
Masonic Cancer Center, University of MinnesotaAdaptNK
Allogeneic KIR-HLA mismatched NK cell infusion enriched for CMV-induced adaptive NK cells
NCAM1, NKG2CPhase 1Relapsed Adult AMLMar 2030

Conditions

Spinal Cord Injury, Acute (1) Relapsed Adult AML (1)

Modalities

other (1), mixed (1)

Companies

S.Biomedics (1) Masonic Cancer Center, University of Minnesota (1)

Related targets

NKG2C (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.